



# Gastric Cancer Histopathology Reporting Proforma

Mandatory questions (i.e. protocol standards) are in bold (e.g. **S1.01**).

## **S1.01 Identification**

Family name

Given name(s)

Date of birth

Sex

- Male  
 Female  
 Intersex/indeterminate

Ethnicity

- Aboriginal/Torres Strait Islander  
 Other ethnicity  
 Unknown

**G1.01 Patient identifiers**

e.g. MRN, IHI or NHI (please indicate which)

Date of request

**S1.02 Accession number**

Requesting doctor - name and contact details

## **Clinical details**

**S1.03 Principal clinician**

**S1.04 Surgeon/proceduralist name and contact details**

**S1.05 Tumour site (location)**

Proximal 1/3

Middle 1/3

Distal 1/3

**S1.06 Type of operation**

Oesophago-gastrectomy

Total gastrectomy

Subtotal gastrectomy (proximal)

Subtotal gastrectomy (distal)

Other (specify)

**S1.07 Preoperative therapy**

Nil

Preoperative chemotherapy

Preoperative radiotherapy

Preoperative chemoradiotherapy

Not stated

**S1.08 Involvement of adjacent organs**

Not stated

Absent

Present

Pancreas

Spleen

Liver

Other (specify)

**S1.09 Distant metastases**

Not stated

Absent

Present

Specify sites

**S1.10 Surgeon's opinion - residual tumour**

**G1.02 Other comments**



## Microscopic findings

### S3.01 Tumour site (location) (tick all that apply)

- Cardia
- Fundus
- Antrum
- Body
- Pylorus
- Greater curve
- Lesser curve
- Anterior wall
- Posterior wall

### S3.02 WHO Histological tumour type

- Tubular adenocarcinoma
- Papillary adenocarcinoma
- Mucinous adenocarcinoma   
(require more than 50% of the tumour to be mucinous)
- Poorly cohesive carcinomas,   
including signet-ring cell carcinoma
- Mixed carcinoma
- Other (specify)

### S3.03 Lauren histological tumour type

- Diffuse
- Intestinal
- Mixed
- Indeterminate (Undifferentiated)
- Other (specify)

### S3.04 Histological grade

- Grade X
- Grade 1
- Grade 2
- Grade 3
- Grade 4

### G3.01 Growth pattern

- Expanding
- Infiltrating

### S3.05 Maximal dimension of tumour

### S3.06 Level of invasion

- Mucosa /lamina propria
- Muscularis mucosa
- Submucosa
- Muscularis propria
- Subserosal connective tissue

### S3.07 Serosal surface involvement

- Absent
- Present

### S3.08 Vascular space invasion:

Small vessels (lymphatic and capillary)

- Absent
- Present

Large vessels (vein and artery)

- Absent
- Present

Perineural growth

- Absent
- Present

### S3.09 Degree of regression after preoperative chemoradiation

- 0 (complete response)
- 1 (moderate response)
- 2 (minimal response)
- 3 (poor response)
- Not applicable

### S3.10 Distance of tumour from margins

From proximal

From distal

From radial/circumferential (proximal/cardia tumours)

### S3.11 Number of involved regional nodes/total number of regional nodes (pN)

 / 

### S3.12 Number of involved non-regional lymph nodes/total number of non-regional lymph nodes (pM)

 / 

### S3.13 Metastatic sites

- Absent
- Present  Specify sites


**S3.14 Other pathologies:**

Gastritis

Absent

Present

Helicobacter infection

Absent

Present

Intestinal metaplasia

Absent

Present

Dyplasia

Absent

Present

Does it involve a margin?

No

Yes

Gastric polyps

Absent

Present

Barrett's mucosa

Absent

Present

Other pathologies (specify):

Text area for specifying other pathologies.

G3.02 Other microscopic comments

Text area for other microscopic comments.

**Ancillary test findings**

G4.01 Ancillary tests

Test 1

Input field for Test 1.

Performing lab

Input field for Performing lab.

Result

Input field for Result.

Conclusion

Input field for Conclusion.

Person responsible for reporting

Input field for Person responsible for reporting.

Test 2

Input field for Test 2.

Performing lab

Input field for Performing lab.

Result

Input field for Result.

Conclusion

Input field for Conclusion.

Person responsible for reporting

Input field for Person responsible for reporting.

**Synthesis and overview**

**S5.01 Tumour stage & stage grouping**

(see p5)

T

Input field for T.

N

Input field for N.

M

Input field for M.

Stage Grouping

Input field for Stage Grouping.

**S5.02 Year of publication and edition of cancer staging system**

Input field for Year of publication and edition of cancer staging system.

G5.01 Diagnostic summary

Include: Specimen type; Tumour site; Histologic type; Involved or close margins with measurements; Pathologic stage and stage grouping

Text area for Diagnostic summary.

G5.02 Other relevant comments

Text area for Other relevant comments.

Worksheet prepared by:

Input field for Worksheet prepared by.

On:

DD - MM - YYYY

## #Tumour Stage

### Primary Tumour (T)

TX	Primary tumour cannot be assessed
T0	No evidence of primary tumour
Tis	Carcinoma in situ: intraepithelial tumour without invasion of the lamina propria
T1	Tumour invades lamina propria, muscularis mucosae, or submucosa
T1a	Tumour invades lamina propria or muscularis mucosae
T1b	Tumour invades submucosa
T2	Tumour invades muscularis propria*
T3	Tumour penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures**, ***
T4	Tumour invades serosa (visceral peritoneum) or adjacent structures**, ***
T4a	Tumour invades serosa (visceral peritoneum)
T4b	Tumour invades adjacent structures
*	Note: A tumour may penetrate the muscularis propria with extension into the gastrohepatic ligaments, or into the greater or lesser omentum, without perforation of the visceral peritoneum covering these structures. In this case, the tumour is classified as T3. If there is perforation of the visceral peritoneum covering the gastric ligaments or the omentum, the tumour should be classified T4.
**	The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine and retroperitoneum.
***	Intramural extension to the duodenum or esophagus is classified by the depth of the greatest invasion in any of these sites, including the stomach.

### Regional Lymph Nodes (N)

NX	Regional lymph node(s) cannot be assessed
N0	No regional lymph node metastasis*
N1	Metastasis in 1-2 regional lymph nodes
N2	Metastasis in 3-6 regional lymph nodes
N3	Metastasis in seven or more regional lymph nodes
N3a	Metastasis in 7-15 regional lymph nodes
N3b	Metastasis in 16 or more regional lymph nodes
*	Note: A designation of pN0 should be used if all examined lymph nodes are negative, regardless of the total number removed and examined.

### Distant Metastasis (M)

M0	No distant metastasis
M1	Distant metastasis

## #Tumour Stage Grouping

### Anatomic Stage/Prognostic Groups

Stage 0	Tis	N0	M0
Stage IA	T1	N0	M0
Stage IB	T2	N0	M0
	T1	N1	M0
Stage IIA	T3	N0	M0
	T2	N1	M0
	T1	N2	M0
Stage IIB	T4a	N0	M0
	T3	N1	M0
	T2	N2	M0
	T1	N3	M0
Stage IIIA	T4a	N1	M0
	T3	N2	M0
	T2	N3	M0
Stage IIIB	T4b	N0	M0
	T4b	N1	M0
	T4a	N2	M0
	T3	N3	M0
Stage IIIC	T4b	N2	M0
	T4b	N3	M0
	T4a	N3	M0
Stage IV	Any T	Any N	M1

# Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science and Business Media LLC, [www.springerlink.com](http://www.springerlink.com).